Q-omics provides the consensus-scored ACTN4P2 profile across patient tissues and cancer cell-line models. ACTN4P2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ACTN4P2 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, ACTN4P2 RNA expression shows 8,980 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, BRCA, and TGCT as cancer lineages where ACTN4P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTN4P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTN4P2 survival associations across molecular data types. ACTN4P2 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTN4P2 RNA expression–survival associations across cancer types. High ACTN4P2 expression shows unfavorable associations in LUAD, UCS, SKCM and PCPG, but favorable associations in READ and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify LUAD as the clearest survival context for ACTN4P2 RNA expression.
This table summarizes ACTN4P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ACTN4P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTN4P2 shows lower tumor expression in KIRP and KIRC and higher tumor expression in BRCA and THCA. The BRCA box plot shows higher ACTN4P2 RNA expression in tumor versus normal tissue (log2 FC = +0.013, t-test p = .025).
This table shows molecular features associated with ACTN4P2 in patient tissues and cancer cell lines. In patient samples, ACTN4P2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
